Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation

Recruiting now · Not applicable

Conditions studied: Hematologic Neoplasms

In brief

Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients´ microbiome following hematopoietic cell transplantation/CAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery and treatment response.

Key facts

Study ID

NCT04691284

Run by

National Cancer Institute, Slovakia

People needed

100

Starts

2021-03-01

Expected to finish

2026-12-01

Last updated by the study team

2025-05-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• signed written informed consent
• aged 18 years or older
• patients planned to be treated by high-dose chemotherapy and hematopoietic cell transplantation or by CAR-T cell therapy in National Cancer Institute, Slovakia

You may not qualify if…

• patients not-matching inclusion criteria

Where it is running

• National Cancer Institute — Bratislava, Slovakia, Slovakia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.